Newron Pharmaceuticals SpA (Newron) is a biopharmaceutical company that focuses on the development of novel therapies for patients with diseases of the central and peripheral nervous system.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Newron’s R&D activities focus on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain. The company has built a balanced and robust pipeline comprised of drug candidates at different clinical stages and has a proven track record of drug development and commercialization. The company has built a balanced and robust pipeline comprised of drug candidates at different clinical stages. Its current pipeline includes Xadago (safinamide), Evenamide, and Ralfinamide. Newron has entered into strategic relationships with established pharmaceutical companies to progress the development and maximize the potential value of its novel CNS compounds. The company also conducts clinical trials in both developed and developing countries and supports the hospitals that work on its clinical trials by providing necessary equipment. Newron is actively engaging potential R&D and business partners to enable its products to be brought to market by companies with the best expertise. In FY2024, the company spent EUR13.6 million on its R&D activities, which grew 3.7% YoY.